Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Child-resistant packaging

This article was originally published in The Tan Sheet

Executive Summary

CPSC proposed rulemaking requiring CRP for all future oral Rx-to-OTC switch drugs to proceed following June 23 vote. Currently, CRP is required for most oral Rx drugs but not for products that switch OTC unless specifically requested by CPSC (1"The Tan Sheet" June 12, p. 4). In a 3-0 vote, the commission authorized the general counsel to draft a proposed rule for Federal Register publication. The rule would apply to switch applications submitted to FDA more than 180 days after a final reg is published; CPSC notices usually provide for a 75-day comment period. Commissioner Mary Gall voiced concerns about placing added burdens on manufacturers, but voted to move forward with the proposed rulemaking so comments can be heard from interested parties

You may also be interested in...



Oral OTC Switches Subject To Mandatory CR Packaging Under Proposed Rule

A proposed rule requiring all oral Rx-to-OTC switch drugs be packaged in child-resistant containers is being considered by the Consumer Product Safety Commission.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091348

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel